Norak Biosciences has signed an agreement to sell selected subsets of its small molecule, compound library to Cropsolution Inc.

The compound library assembled by RTP-based Norak has over 900,000 drug-like, small molecules that the company is actively screening in its G protein-coupled receptor (GPCR)-based drug discovery program.

With the purchase, Cropsolution will utilize the selected compounds in its agriculture discovery program.

Cropsolution, also based in RTP, is an agricultural biotechnology company focused on the discovery and development of chemical products for the crop protection market.

Norak is a biopharmaceutical company utilizing its proprietary Transfluor technology to discover GPCR-based drugs. The technology, licensed from Duke University in 1999, is a patented, universal drug discovery technology designed as a method for screening potential drug candidates against GPCR targets, whether known or orphan.